Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroids are frequently used in patients with metastatic non-small cell lung cancer (mNSCLC), but they could be detrimental for patients treated with immune checkpoint inhibitors (ICIs). Here, we assessed the association between early use of steroids, clinical outcomes and peripheral immune blood cells modulation in patients with mNSCLC treated with ICIs. METHODS: We reviewed patients with mNSCLC treated at our institution between April 2013 and December 2017. Early use of steroids was defined as the use of a daily prednisone-equivalent dose ≥10 mg for at least 1 day within 28 days after ICI initiation. Peripheral immune blood cell counts were retrieved at baseline and at 4 and 6 weeks after ICI initiation. RESULTS: Out of 151 patients included, 35 (23%) made early use of steroids that was associated with poor disease control (OR 0.32, p=0.006), progression-free survival (HR 1.80, p=0.003) and overall survival (HR 2.60, p<0.001). Early use of steroids significantly correlated with higher median absolute neutrophil count, neutrophil to lymphocyte ratio (NLR) and derived NLR, and lower median absolute and relative eosinophil count, both at 4 and 6 weeks after ICI initiation. CONCLUSIONS: In patients with mNSCLC treated with ICIs, early use of steroids was associated with worse clinical outcomes and remarkable modulation of peripheral blood immune cells, which could contribute to restraining the activation of antitumour immunity. If confirmed in prospective studies, these findings would highlight the importance of carefully evaluating and, whenever possible, avoiding steroids during early phases of ICI treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the other hand, early use of steroids was associated with worse clinical outcomes and remarkable modulation of peripheral blood immune cells (including the decrease of the AEC), which could contribute to restraining the activation of antitumour immunity.35”
The cited source says what the claim attributes to it.
In the citing paper
“Of note, high neutrophil to lymphocyte ratio and a low relative eosinophil count at 4 and 6 weeks were consistently associated with reduced benefit from ICIs.”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [30]
In the citing paper
“Interestingly, this report showed that the early use of CS induces remarkable modulation of peripheral blood immune cells with increase in neutrophil to lymphocyte ratio and absolute neutrophil count and decrease in absolute eosinophil count (AEC) and relative eosinophil count.30”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“3–6 Despite the efficacy of ICIs, only a limited number of patients actually benefit from these agents.”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · cited 7×
“In conclusion, we showed that the early use of steroids is associated with modulation in peripheral blood cells and significantly worse disease control, PFS and OS in patients with advanced NSCLC treated with ICIs.”
InfluentialA note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071
Self-citationAssociation of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 986
Interleukin-1 Type II Receptor: A Decoy Target for IL-1 That Is Regulated by IL-4
Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J. G., Dower, S. K., Sims, J. E., & Mantovani, A. (1993) · Science · doi:10.1126/science.8332913 · Cited by 980
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Self-citationMeagher, L. C., Cousin, J. M., Seckl, J. R., & Haslett, C. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.11.4422 · Cited by 608
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Bagley, S. J., Kothari, S., Aggarwal, C., Bauml, J. M., Alley, E. W., Evans, T. L., Kosteva, J. A., Ciunci, C. A., Gabriel, P. E., Thompson, J. C., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.013 · Cited by 511
Glucocorticoids in T cell apoptosis and function
Herold, M. J., McPherson, K. G., & Reichardt, H. M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5390-y · Cited by 397
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0305 · Cited by 341
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab
Scott, S. C., & Pennell, N. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.004 · Cited by 202
Heppt, M. V., Heinzerling, L., Kähler, K. C., Forschner, A., Kirchberger, M. C., Loquai, C., Meissner, M., Meier, F., Terheyden, P., Schell, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.038 · Cited by 199
Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R., Jinushi, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.017 · Cited by 198
Aguiar, P. N., De Mello, R. A., Hall, P., Tadokoro, H., & Lima Lopes, G. D. (2017) · Immunotherapy · doi:10.2217/imt-2016-0150 · Cited by 197
Steroids, stress and the gut microbiome-brain axis
Tetel, M. J., de Vries, G. J., Melcangi, R. C., Panzica, G., & O'Mahony, S. M. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12548 · Cited by 187
Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A., Janku, F., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0534-0 · Cited by 179
Suh, K. J., Kim, S. H., Kim, Y. J., Kim, M., Keam, B., Kim, T. M., Kim, D.-W., Heo, D. S., & Lee, J. S. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2092-x · Cited by 171
Zer, A., Sung, M. R., Walia, P., Khoja, L., Maganti, M., Labbe, C., Shepherd, F. A., Bradbury, P. A., Feld, R., Liu, G., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.008 · Cited by 134
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 115
Russo, A., Franchina, T., Ricciardi, G. R. R., Battaglia, A., Scimone, A., Berenato, R., Giordano, A., & Adamo, V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26609 · Cited by 111
Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes
Lanza, L., Scudeletti, M., Puppo, F., Bosco, O., Peirano, L., Filaci, G., Fecarotta, E., Vidali, G., & Indiveri, F. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1996.tb08306.x · Cited by 109
Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures
Franchimont, D. P., Louis, E. J., Dewé, W., Martens, H., VRINDTS‐GEVAERT, Y., Groote, D. D., Bélaïche, J., & Geenen, V. G. (1998) · Regulatory Peptides · doi:10.1016/s0167-0115(97)01063-x · Cited by 108
Putzu, C., Cortinovis, D. L., Colonese, F., Canova, S., Carru, C., Zinellu, A., & Paliogiannis, P. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2182-4 · Cited by 83
Libert, C., & Dejager, L. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.041 · Cited by 69
Park, W., Kwon, D., Saravia, D., Desai, A. J., Vargas, F., Dinali, M. E., Warsch, J. R. L., Elias, R. M., Chae, Y. K., Kim, D. W., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.007 · Cited by 62
Dumenil, C., Massiani, M.-A., Dumoulin, J., Giraud, V., Labrune, S., Chinet, T., & Giroux Leprieur, E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195945 · Cited by 60
Remón, J., Vilariño, N., & Reguart, N. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.002 · Cited by 50
Advances in the understanding of cancer immunotherapy
Shore, N. D. (2014) · British Journal of Urology · doi:10.1111/bju.12692 · Cited by 41
Hájková, M., Heřmánková, B., Javorková, E., Boháčová, P., Zajícová, A., Holáň, V., & Krulová, M. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9703-3 · Cited by 37
Fucà, G., Galli, G., Poggi, M. M., Russo, G. L., Proto, C., Imbimbo, M., Vitali, M., Ganzinelli, M., Lanti, C., Molino, G., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0599-5 · Cited by 29
Self-citationImmunotherapy-based combinations: an update
Fucà, G., de Braud, F., & Nicola, M. D. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000466 · Cited by 27
Self-citationMehra, N., Sharp, A., Lorente, D., Dolling, D. I., Sumanasuriya, S., Johnson, B., Dearnaley, D. P., Parker, C. C., & Bono, J. S. D. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.05.012 · Cited by 21
Edward, J. A., Sanyal, M., Le, W., Soudry, E., Ramakrishnan, V. R., Bravo, D. T., Nguyen, A. L., Zarabanda, D., Kingdom, T. T., Hwang, P. H., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.02.002 · Cited by 13 · cited 1×
“20 30 There are several reasons why steroids can affect the outcomes of anti PD-1/PD-L1 therapy, including impairment of T-cell activation(31) and inflammation,(32) microbiome modifications,(33) Th1 to Th2 phenotype skewing,(34) 35 and T regulatory cells recruitment.(36) All these events, along with the capacity of co…”
Martínez-Bernal, G., Mezquita, L., Auclin, É., Ferrara, R., Planchard, D., Masip, J. R., Lahmar, J., Boucher, M.-É., Caramella, C., Adam, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380.025 · Cited by 13
Self-citationThe Academy of Science of St. Louis
Grier, N. M. (1918) · Science · doi:10.1126/science.48.1231.124 · Cited by 4
Research works printed but not linked: 1
- Leighl N, Gandhi L, Hellmann MD Pembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use. J Thorac Oncol 2015; 10: S66– S890.26710300
Cited by
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, A.-L., Hsu, C., Chan, S. L., Choo, S.-P., & Kudo, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.025 · Cited by 528
Antiemetics: ASCO Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01296 · Cited by 470
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Stress and cancer: mechanisms, significance and future directions
Eckerling, A., Ricon-Becker, I., Sorski, L., Sandbank, E., & Ben-Eliyahu, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00395-5 · Cited by 348
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, E., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 309
“Fucà et al (45) studied 35 patients who received early treatment with steroids, defined as corticosteroids ≥10 mg for at least 1 day within 28 days after ICI initiation, among”
BackgroundInfluential
Metadata
- Authors
- Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., Torri, V., Colombo, M. P., Vernieri, C., Balsari, A., de Braud, F., Garassino, M. C., & Signorelli, D.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Mario Negri Institute for Pharmacological Research (IT)
- IFOM (IT)
- University of Milan (IT)
- Corresponding author
- Garassino, Marina Chiara
- ORCID
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2019
- Volume
- 4
- Issue
- 1
- Pages
- e000457
- ISSN
- 2059-7029 (ISSN-L)
- PMC
- PMC6435242
- OpenAlex
- W2918511688
- Semantic Scholar
- 86a1a0bf0fd397c0dbc677fe15459d020d6eede0
- Cited by
- 209
- References
- 49
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 35 · 2022: 26 · 2021: 41 · 2020: 41 · 2019: 15
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 645 d)
- Locations
- ESMO Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Ministero della Salute (CUP: B43C17000350001)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- metastatic non-small cell lung cancer, immune checkpoint inhibitors, corticosteroids, peripheral immune cells, neutrophil-to-lymphocyte ratio, eosinophil count, disease control, progression-free survival, overall survival, antitumor immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
